Aquyre Biosciences, Inc. Appoints Dr. Wilson Tsai to its Medical Advisory Board
WESTON, Mass.– Aquyre Biosciences, Inc. is pleased to announce the appointment of Dr. Wilson Tsai to its Medical Advisory Board where he will support its strategic initiatives and provide valuable clinical expertise. The appointment comes at a significant time for the business, as Aqyure Biosciences has commercially launched its FDA-registered CelTivity™ Biopsy Assessment System within the U.S. market.
The Aquyre CelTivity™ system captures cellular activity data from fresh, live biopsies. The result is access to intraprocedural cellular information, allowing physicians to identify the most active cells, such as cancer and immune cells, to adequately assess tissue.
“I’m honored and excited to join Aqyure’s Medical Advisory Board,” says Dr. Tsai. “The CelTivity™ system will revolutionize the way tissue biopsies are both adequately assessed and diagnosed while filling a huge gap in the continuum of care that currently exists. Moreover, I look forward to working with the company on clinical applications, strategy, and the integration of Artificial Intelligence.1
“We are honored to have Dr. Tsai join our Medical Advisory Board,” says Bertrand De Poly, Co-founder and Chief Executive Officer of Aquyre Biosciences. “With CelTivity™ and its Dynamic Cell Imaging™ capabilities, Dr. Tsai’s expertise will be key as we launch within the U.S. market and further develop our product offering in the future.”
Welcome aboard, Dr. Tsai!
To learn more about Aquyre Biosciences and CelTivity visit www.aquyre.com.
About Aquyre Biosciences
Aquyre Biosciences, Inc is the creator of CelTivity™, the industry leader in two-minute lung biopsy adequacy assessment. Powered by two proprietary technologies including Dynamic Cell Imaging™ (DCI), CelTivity can scan a biopsy and measure intracellular and metabolic activity throughout extracted tissue. This activity is presented in a heatmap, making it easy to interpret. The assessment does not require any cutting or staining, meaning the same tissue accessed for adequacy can go to final pathology to review for cancer, granuloma, lymphocytes, and more. Aquyre Biosciences is headquartered out of Weston, Mass. For more information, please visit www.aquyre.com
About Dr. Wilson Tsai
Dr. Wilson Tsai is a minimally invasive thoracic surgeon and the Director of the Thoracic Surgical Program at John Muir Health in California. He is board-certified in thoracic surgery and has been a member of the American Association for Thoracic Surgery since 1996. Since Dr. Tsai’s appointment to the directorship at John Muir Health, he has established a nationally recognized minimally invasive thoracic program that specializes in all aspects of benign and malignant esophageal and lung diseases. With this, Dr. Tsai is committed to providing his patients with the latest advancements and treatment options, to include robotic surgery and robotic bronchoscopy.